CD8A and type 1 diabetes mellitus: We chose to test our workflow in engineered IGRP-reactive CD8+ T cells, as a number of studies have explored the importance of this antigen in T1D as a target for human CD8+ T cells in circulation (5, 23) and in situ (6).